Home Data-Driven Thinking Is Ad Tech Good For Your Health?

Is Ad Tech Good For Your Health?

SHARE:

raykingman“Data-Driven Thinking” is written by members of the media community and contains fresh ideas on the digital revolution in media.

Today’s column is written by Ray Kingman, CEO at Semcasting.

Whether you’re watching television or listening to the radio, you’re bound to catch an ad soliciting participants for a clinical trial.

These trials can’t take just anyone; participants must meet strict requirements, including age, lifestyle or prescription drug use. Pharmaceutical companies running those ads are often looking for needles in a haystack, but unfortunately, they’re using one of the costliest shotgun methods available.

Using high-visibility but inefficient television media to reach specific audiences is just one symptom of the challenges facing health care, which desperately needs to move into the digital age.

When we discuss the big data revolution transforming health care, we tend to fixate on the diagnostic and cost-savings benefits of patient records being available to health care providers on demand. Questions about how data is collected, distributed and privacy-protected soon follow.

What gets less attention is how data could be applied to improve health care distribution. How could existing health care and pharmaceutical data sets be combined with commercial data to provide cost-saving benefits in many health care distribution information systems?

Could applying ad tech’s capacity to leverage analytics advance health care services?

Localizing Our Understanding Of Pharmaceutical Consumption

Much has been written about America’s deadly opioid crisis, and CDC data has helped paint a vivid picture of its widespread impact on society. But a national profile doesn’t mean a lot to local health care providers or communities on the ground that may not have the tools to deal with an opioid problem.

The most insightful data may exist in the commercial sector. Local pharmacies fill prescriptions and over-the-counter medications. Doctors write these prescriptions and insurance companies provide benefit coverage.

Communities and providers can draw real insights at the local level by leveraging sales transactions data of highly correlated medications in the supply chain and combining them with local community demographic data sets. Executed in a privacy-safe way, those insights could help at-risk populations by taking preventative action through communication and outreach.

The kind of data-driven targeting tools commonly used throughout ad tech aren’t limited to specific diseases or public health issue. Like all tools, it’s really a question of where we choose to apply them.

A Better Health Care Delivery System

Over the past few years, the Affordable Care Act has begun to transform the American health care system. We are seeing a series of experiments on the health care service model so that it can still deliver the care we get today at a lower cost.

Bending the cost curve of health care could hinges on creating efficiencies in diagnostics, logistics and information transfer through the use of big data analytics and some of the optimization techniques currently used in programmatic. And while analytics and a digitally enabled supply chain may be our greatest asset in this battle, we don’t know who will be able to put these tools to best use.

In the same way that Amazon used consumer transaction data to create a high-value distribution engine for delivering just-in-time goods and services at a transparent price, health care delivery can also optimize the mountains of data about provider services, pharmaceutical distribution and local demographic profiles.

Localizing health care specialty coverage to at-risk populations will help control costs. Optimizing pharmaceutical inventory to patient disease frequencies within a trade area of each hospital will lower drug costs. Taking promotional overhead out of clinical trials will also bend the cost curve. Likewise, improving patient-doctor communications and access through opt-in data sharing and just-in-time care, we can bend the cost curve again.

The race to build a better health care delivery system is well underway, but the question isn’t so much about what it will look like but how health care’s established players will take advantage of the digital revolution?

Follow Semcasting (@Semcasting) and AdExchanger (@adexchanger) on Twitter.

Tagged in:

Must Read

New WBD Report Makes The Case For Getting The Measurement Basics Right

Warner Bros. Discovery has a new white paper analyzing the data and methodologies of five top video measurement providers: VideoAmp, iSpot, Comscore, Innovid and Samba.

Monopoly Man looks on at the DOJ vs. Google ad tech antitrust trial (comic).

Google And The DOJ Filed Their Proposed Final Judgments In The Ad Tech Case – Here’s What They’re Still Arguing About

Google and the Department of Justice filed the next round of paperwork that will determine what Google’s punishment will look like in the ad tech antitrust case.

T-Mobile Brings Its Mobile Data Exclusively To Vistar To Scale Up DOOH Targeting

Advertisers can now use Vistar to activate both off-the-shelf and custom audiences built on T-Mobile’s first-party location and app data.

Privacy! Commerce! Connected TV! Read all about it. Subscribe to AdExchanger Newsletters

Apple Has Far-Reaching Plans To Block Hundreds Of Programmatic Data Companies From iOS

Apple’s WebKit crackdown appears to extend well beyond The Trade Desk, putting hundreds of ad tech, data and identity vendors on a mysterious, dynamically updated block list.

Josh Reed, Zoom's VP of brand and content, speaking at AdExchanger's Programmatic IO event in New York City (September 28, 2006)

Zoom’s Marketing Challenge Is That It’s Too Well Known For Its Own Good

Zoom has 99% unaided brand awareness, which sounds great on paper. But there’s a catch: Most people still think it’s just a video-call app.

Why Agencies Think They Shouldn’t Own Agentic AI Tools Or The Data Used To Build Them

Agencies are differentiating their tech stacks by building custom agentic AI tools for their clients. And they’re rethinking owning those AI tools – particularly since licensing them creates new revenue streams.